Flenady, V, Middleton, P, Smith, GC, Duke, W, Erwich, JJ, Khong, TY, et al. Stillbirths: the way forward in high-income countries. Lancet. 2011; 377: 1703–17.
Gardosi, J, Madurasinghe, V, Williams, M, Malik, A, Francis, A. Maternal and fetal risk factors for stillbirth: population based study. BMJ. 2013; 346: f108.
Barker, DJ, Osmond, C. Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. Lancet. 1986; 1: 1077–81.
Mifsud, W, Sebire, NJ. Placental pathology in early-onset and late-onset fetal growth restriction. Fetal Diagn Ther. 2014; 36: 117–28.
Gordijn, SJ, Beune, IM, Thilaganathan, B, Papageorghiou, A, Baschat, AA, Baker, PN, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016; 48: 333–9.
Lean, SC, Derricott, H, Jones, RL, Heazell, AEP. Advanced maternal age and adverse pregnancy outcomes: a systematic review and meta-analysis. PLoS ONE. 2017; 12: e0186287.
Flenady, V, Koopmans, L, Middleton, P, Froen, JF, Smith, GC, Gibbons, K, et al. Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. Lancet. 2011; 377: 1331–40.
Schieve, LA, Meikle, SF, Ferre, C, Peterson, HB, Jeng, G, Wilcox, LS. Low and very low birth weight in infants conceived with use of assisted reproductive technology. N Engl J Med. 2002; 346: 731–7.
Lawn, JE, Blencowe, H, Waiswa, P, Amouzou, A, Mathers, C, Hogan, D, et al. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet. 2016; 387: 587–603.
McDonald, SD, Han, Z, Mulla, S, Murphy, KE, Beyene, J, Ohlsson, A. Preterm birth and low birth weight among in vitro fertilization singletons: a systematic review and meta-analyses. Eur J Obstet Gynecol Reprod Biol. 2009; 146: 138–48.
Helmerhorst, FM, Perquin, DA, Donker, D, Keirse, MJ. Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies. BMJ. 2004; 328: 261.
Steegers, EA, von Dadelszen, P, Duvekot, JJ, Pijnenborg, R. Pre-eclampsia. Lancet. 2010; 376: 631–44.
Schreiber, K, Radin, M, Sciascia, S. Current insights in obstetric antiphospholipid syndrome. Curr Opin Obstet Gynecol. 2017; 29: 397–403.
Sammaritano, LR. Management of systemic lupus erythematosus during pregnancy. Annu Rev Med. 2017; 68: 271–85.
Foo, FL, Mahendru, AA, Masini, G, Fraser, A, Cacciatore, S, MacIntyre, DA, et al. Association between prepregnancy cardiovascular function and subsequent preeclampsia or fetal growth restriction. Hypertension. 2018; 72: 442–50.
Tay, J, Foo, L, Masini, G, Bennett, PR, McEniery, CM, Wilkinson, IB, et al. Early and late preeclampsia are characterized by high cardiac output, but in the presence of fetal growth restriction, cardiac output is low: insights from a prospective study. Am J Obstet Gynecol. 2018; 218: 517. e1–e12.
Simcox, LE, Ormesher, L, Tower, C, Greer, IA. Thrombophilia and pregnancy complications. Int J Mol Sci. 2015; 16: 28418–28.
Rodger, MA, Gris, JC, de Vries, JIP, Martinelli, I, Rey, E, Schleussner, E, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet. 2016; 388: 2629–41.
Kingdom, JC, Drewlo, S. Is heparin a placental anticoagulant in high-risk pregnancies? Blood. 2011; 118: 4780–8.
Bundhun, PK, Soogund, MZ, Huang, F. Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: a meta-analysis of studies published between years 2001-2016. J Autoimmun. 2017; 79: 17–27.
Chakravarty, EF, Khanna, D, Chung, L. Pregnancy outcomes in systemic sclerosis, primary pulmonary hypertension, and sickle cell disease. Obstet Gynecol. 2008; 111: 927–34.
Greutmann, M, Pieper, PG. Pregnancy in women with congenital heart disease. Eur Heart J. 2015; 36: 2491–9.
Luewan, S, Srisupundit, K, Tongsong, T. Outcomes of pregnancies complicated by beta-thalassemia/hemoglobin E disease. Int J Gynaecol Obstet. 2009; 104: 203–5.
Mortola, JP, Frappell, PB, Aguero, L, Armstrong, K. Birth weight and altitude: a study in Peruvian communities. J Pediatr. 2000; 136: 324–9.
Stein, AD, Lumey, LH. The relationship between maternal and offspring birth weights after maternal prenatal famine exposure: the Dutch Famine Birth Cohort Study. Hum Biol. 2000; 72: 641–54.
Saccone, G, Berghella, V, Sarno, L, Maruotti, GM, Cetin, I, Greco, L, et al. Celiac disease and obstetric complications: a systematic review and metaanalysis. Am J Obstet Gynecol. 2016; 214: 225–34.
Khashan, AS, Henriksen, TB, Mortensen, PB, McNamee, R, McCarthy, FP, Pedersen, MG, et al. The impact of maternal celiac disease on birthweight and preterm birth: a Danish population-based cohort study. Hum Reprod. 2010; 25: 528–34.
Anjum, N, Baker, PN, Robinson, NJ, Aplin, JD. Maternal celiac disease autoantibodies bind directly to syncytiotrophoblast and inhibit placental tissue transglutaminase activity. Reprod Biol Endocrinol. 2009; 7: 16.
Kiefte-de Jong, JC, Jaddoe, VW, Uitterlinden, AG, Steegers, EA, Willemsen, SP, Hofman, A, et al. Levels of antibodies against tissue transglutaminase during pregnancy are associated with reduced fetal weight and birth weight. Gastroenterology. 2013; 144: 726–35. e2.
Suter, MA, Anders, AM, Aagaard, KM. Maternal smoking as a model for environmental epigenetic changes affecting birthweight and fetal programming. Mol Hum Reprod. 2013; 19: 1–6.
Blatt, K, Moore, E, Chen, A, Van Hook, J, DeFranco, EA. Association of reported trimester-specific smoking cessation with fetal growth restriction. Obstet Gynecol. 2015; 125: 1452–9.
Carter, RC, Jacobson, JL, Molteno, CD, Dodge, NC, Meintjes, EM, Jacobson, SW. Fetal alcohol growth restriction and cognitive impairment. Pediatrics. 2016; 138: e20160775.
Carter, RC, Wainwright, H, Molteno, CD, Georgieff, MK, Dodge, NC, Warton, F, et al. Alcohol, methamphetamine, and marijuana exposure have distinct effects on the human placenta. Alcohol Clin Exp Res. 2016; 40: 753–64.
Gundogan, F, Elwood, G, Longato, L, Tong, M, Feijoo, A, Carlson, RI, et al. Impaired placentation in fetal alcohol syndrome. Placenta. 2008; 29: 148–57.
Committee on Obstetric Practice. Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol. 2017; 130: e81–94.
Zedler, BK, Mann, AL, Kim, MM, Amick, HR, Joyce, AR, Murrelle, EL, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction. 2016; 111: 2115–28.
Soto, E, Bahado-Singh, R. Fetal abnormal growth associated with substance abuse. Clin Obstet Gynecol. 2013; 56: 142–53.
Bada, HS, Das, A, Bauer, CR, Shankaran, S, Lester, B, Wright, LL, et al. Gestational cocaine exposure and intrauterine growth: maternal lifestyle study. Obstet Gynecol. 2002; 100: 916–24.
Kalaitzopoulos, DR, Chatzistergiou, K, Amylidi, AL, Kokkinidis, DG, Goulis, DG. Effect of methamphetamine hydrochloride on pregnancy outcome: a systematic review and meta-analysis. J Addict Med. 2018; 12: 220–6.
Ray, S, Stowe, ZN. The use of antidepressant medication in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2014; 28: 71–83.
Bloise, E, Feuer, SK, Rinaudo, PF. Comparative intrauterine development and placental function of ART concepti: implications for human reproductive medicine and animal breeding. Hum Reprod Update. 2014; 20: 822–39.
Snijders, RJ, Sherrod, C, Gosden, CM, Nicolaides, KH. Fetal growth retardation: associated malformations and chromosomal abnormalities. Am J Obstet Gynecol. 1993; 168: 547–55.
Rochelson, B, Kaplan, C, Guzman, E, Arato, M, Hansen, K, Trunca, C. A quantitative analysis of placental vasculature in the third-trimester fetus with autosomal trisomy. Obstet Gynecol. 1990; 75: 59–63.
Fujimoto, A, Wilson, MG. Growth retardation in Wolf-Hirschhorn syndrome. Hum Genet. 1990; 84: 296–7.
Sagi-Dain, L, Peleg, A, Sagi, S. Risk for chromosomal aberrations in apparently isolated intrauterine growth restriction: A systematic review. Prenat Diagn. 2017; 37: 1061–6.
Khoury, MJ, Erickson, JD, Cordero, JF, McCarthy, BJ. Congenital malformations and intrauterine growth retardation: a population study. Pediatrics. 1988; 82: 83–90.
Sun, L, Macgowan, CK, Sled, JG, Yoo, SJ, Manlhiot, C, Porayette, P, et al. Reduced fetal cerebral oxygen consumption is associated with smaller brain size in fetuses with congenital heart disease. Circulation. 2015; 131: 1313–23.
Naeye, RL. Unsuspected organ abnormalities associated with congenital heart disease. Am J Pathol. 1965; 47: 905–15.
Hamilton, ST, Scott, G, Naing, Z, Iwasenko, J, Hall, B, Graf, N, et al. Human cytomegalovirus-induces cytokine changes in the placenta with implications for adverse pregnancy outcomes. PLoS ONE. 2012; 7: e52899.
Adams Waldorf, KM, McAdams, RM. Influence of infection during pregnancy on fetal development. Reproduction. 2013; 146: R151–62.
Umbers, AJ, Aitken, EH, Rogerson, SJ. Malaria in pregnancy: small babies, big problem. Trends Parasitol. 2011; 27: 168–75.
McCarthy, FP, Giles, ML, Rowlands, S, Purcell, KJ, Jones, CA. Antenatal interventions for preventing the transmission of cytomegalovirus (CMV) from the mother to fetus during pregnancy and adverse outcomes in the congenitally infected infant. Cochrane Database Syst Rev. 2011; 3: CD008371.
Sassoon, DA, Castro, LC, Davis, JL, Hobel, CJ. Perinatal outcome in triplet versus twin gestations. Obstet Gynecol. 1990; 75: 817–20.
Coutinho Nunes, F, Domingues, AP, Vide Tavares, M, Belo, A, Ferreira, C, Fonseca, E, et al. Monochorionic versus dichorionic twins: are obstetric outcomes always different? J Obstet Gynaecol. 2016; 36: 598–601.
Stirrup, OT, Khalil, A, D’Antonio, F, Thilaganathan, B, Southwest Thames Obstetric Research Collaborative. Fetal growth reference ranges in twin pregnancy: analysis of the Southwest Thames Obstetric Research Collaborative (STORK) multiple pregnancy cohort. Ultrasound Obstet Gynecol. 2015; 45: 301–7.
Cheong-See, F, Schuit, E, Arroyo-Manzano, D, Khalil, A, Barrett, J, Joseph, KS, et al. Prospective risk of stillbirth and neonatal complications in twin pregnancies: systematic review and meta-analysis. BMJ. 2016; 354: i4353.
Hall, JG. Twinning. Lancet. 2003; 362: 735–43.
Sparks, TN, Nakagawa, S, Gonzalez, JM. Hypertension in dichorionic twin gestations: how is birthweight affected? J Matern Fetal Neonatal Med. 2017; 30: 380–5.
Lewi, L, Cannie, M, Blickstein, I, Jani, J, Huber, A, Hecher, K, et al. Placental sharing, birthweight discordance, and vascular anastomoses in monochorionic diamniotic twin placentas. Am J Obstet Gynecol. 2007; 197: 587. e1–8.
Audette, MC, Kingdom, JC. Screening for fetal growth restriction and placental insufficiency. Semin Fetal Neonatal Med. 2018; 23: 119–25.
Kingdom, JC, Audette, MC, Hobson, SR, Windrim, RC, Morgen, E. A placenta clinic approach to the diagnosis and management of fetal growth restriction. Am J Obstet Gynecol. 2018; 218: S803–17.
Pay, AS, Wiik, J, Backe, B, Jacobsson, B, Strandell, A, Klovning, A. Symphysis-fundus height measurement to predict small-for-gestational-age status at birth: a systematic review. BMC Pregnancy Childbirth. 2015; 15: 22.
Robert Peter, J, Ho, JJ, Valliapan, J, Sivasangari, S. Symphysial fundal height (SFH) measurement in pregnancy for detecting abnormal fetal growth. Cochrane Database Syst Rev. 2015; 9: CD008136.
Hadlock, FP, Harrist, RB, Sharman, RS, Deter, RL, Park, SK. Estimation of fetal weight with the use of head, body, and femur measurements—a prospective study. Am J Obstet Gynecol. 1985; 151: 333–7.
Papageorghiou, AT, Ohuma, EO, Altman, DG, Todros, T, Cheikh Ismail, L, Lambert, A, et al. International standards for fetal growth based on serial ultrasound measurements: the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project. Lancet. 2014; 384: 869–79.
Gardosi, J. Customized fetal growth standards: rationale and clinical application. Semin Perinatol. 2004; 28: 33–40.
Ego, A, Subtil, D, Grange, G, Thiebaugeorges, O, Senat, MV, Vayssiere, C, et al. Customized versus population-based birth weight standards for identifying growth restricted infants: a French multicenter study. Am J Obstet Gynecol. 2006; 194: 1042–9.
Reddy, M, Wallace, EM, Mockler, JC, Stewart, L, Knight, M, Hodges, R, et al. Maternal Asian ethnicity and obstetric intrapartum intervention: a retrospective cohort study. BMC Pregnancy Childbirth. 2017; 17: 3.
Lockie, E, McCarthy, EA, Hui, L, Churilov, L, Walker, SP. Feasibility of using self-reported ethnicity in pregnancy according to the gestation-related optimal weight classification: a cross-sectional study. BJOG. 2018; 125: 704–9.
Kiserud, T, Piaggio, G, Carroli, G, Widmer, M, Carvalho, J, Neerup Jensen, L, et al. The World Health Organization Fetal Growth Charts: A Multinational Longitudinal Study of Ultrasound Biometric Measurements and Estimated Fetal Weight. PLoS Medicine. 2017; 14: e1002220.
Bricker, L, Medley, N, Pratt, JJ. Routine ultrasound in late pregnancy (after 24 weeks’ gestation). Cochrane Database Syst Rev. 2015; 6: CD001451.
Sovio, U, White, IR, Dacey, A, Pasupathy, D, Smith, GCS. Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study: a prospective cohort study. Lancet. 2015; 386: 2089–97.
Monier, I, Blondel, B, Ego, A, Kaminiski, M, Goffinet, F, Zeitlin, J. Poor effectiveness of antenatal detection of fetal growth restriction and consequences for obstetric management and neonatal outcomes: a French national study. BJOG. 2015; 122: 518–27.
Deter, RL. Individualized growth assessment: evaluation of growth using each fetus as its own control. Semin Perinatol. 2004; 28: 23–32.
Kingdom, JC, Burrell, SJ, Kaufmann, P. Pathology and clinical implications of abnormal umbilical artery Doppler waveforms. Ultrasound Obstet Gynecol. 1997; 9: 271–86.
Alfirevic, Z, Stampalija, T, Dowswell, T. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. Cochrane Database Syst Rev. 2017; 6: CD007529.
Alfirevic, Z, Stampalija, T, Medley, N. Fetal and umbilical Doppler ultrasound in normal pregnancy. Cochrane Database Syst Rev. 2015; 4: CD001450.
Rodriguez, A, Tuuli, MG, Odibo, AO. First-, second-, and third-trimester screening for preeclampsia and intrauterine growth restriction. Clin Lab Med. 2016; 36: 331–51.
Roberts, LA, Ling, HZ, Poon, L, Nicolaides, KH, Kametas, NA. Maternal hemodynamics, fetal biometry and Dopplers in pregnancies followed up for suspected fetal growth restriction. Ultrasound Obstet Gynecol. 2018; 52: 507–14.
Smith, GC. First-trimester determination of complications of late pregnancy. JAMA. 2010; 303: 561–2.
Gaccioli, F, Aye, I, Sovio, U, Charnock-Jones, DS, Smith, GCS. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. Am J Obstet Gynecol. 2018; 218: S725–37.
Tan, MY, Poon, LC, Rolnik, DL, Syngelaki, A, de Paco Matallana, C, Akolekar, R, et al. Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. Ultrasound Obstet Gynecol. 2018; 52: 52–9.
Sovio, U, Smith, GCS. The effect of customization and use of a fetal growth standard on the association between birthweight percentile and adverse perinatal outcome. Am J Obstet Gynecol. 2018; 218: S738–44.
Griffin, M, Seed, PT, Duckworth, S, North, R, Myers, J, Mackillop, L, et al. Predicting delivery of a small-for-gestational-age infant and adverse perinatal outcome in women with suspected pre-eclampsia. Ultrasound Obstet Gynecol. 2018; 51: 387–95.
Sharp, A, Chappell, LC, Dekker, G, Pelletier, S, Garnier, Y, Zeren, O, et al. Placental Growth Factor informed management of suspected pre-eclampsia or fetal growth restriction: the MAPPLE cohort study. Pregnancy Hypertens. 2018; 14: 228–33.
Ormesher, L, Johnstone, ED, Shawkat, E, Dempsey, A, Chmiel, C, Ingram, E, et al. A clinical evaluation of placental growth factor in routine practice in high-risk women presenting with suspected pre-eclampsia and/or fetal growth restriction. Pregnancy Hypertens. 2018; 14: 243–9.
Griffin, M, Seed, PT, Webster, L, Myers, J, MacKillop, L, Simpson, N, et al. Diagnostic accuracy of placental growth factor and ultrasound parameters to predict the small-for-gestational-age infant in women presenting with reduced symphysis-fundus height. Ultrasound Obstet Gynecol. 2015; 46: 182–90.
Lees, C, Marlow, N, Arabin, B, Bilardo, CM, Brezinka, C, Derks, JB, et al. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol. 2013; 42: 400–8.
Figueras, F, Caradeux, J, Crispi, F, Eixarch, E, Peguero, A, Gratacós, E. Diagnosis and surveillance of late-onset fetal growth restriction. Am J Obstet Gynecol. 2018; 218: S790–802. e1.
Figueras, F, Gratacós, E. An integrated approach to fetal growth restriction. Best Pract Res Clin Obstet Gynaecol. 2017; 38: 48–58.
Sebire, NJ. Umbilical artery Doppler revisited: pathophysiology of changes in intrauterine growth restriction revealed. Ultrasound Obstet Gynecol. 2003; 21: 419–22.
Caradeux, J, Martinez-Portilla, RJ, Basuki, TR, Kiserud, T, Figueras, F. Risk of fetal death in growth-restricted fetuses with umbilical and/or ductus venosus absent or reversed end-diastolic velocities before 34 weeks of gestation: a systematic review and meta-analysis. Am J Obstet Gynecol. 2018; 218: S774–82. e21.
Vollgraff Heidweiller-Schreurs, CA, De Boer, MA, Heymans, MW, Schoonmade, LJ, Bossuyt, PMM, Mol, BWJ, et al. Prognostic accuracy of cerebroplacental ratio and middle cerebral artery Doppler for adverse perinatal outcome: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018; 51: 313–22.
Grivell, RM, Alfirevic, Z, Gyte, GM, Devane, D. Antenatal cardiotocography for fetal assessment. Cochrane Database Syst Rev. 2015; 9: CD007863.
Pattison, N, McCowan, L. Cardiotocography for antepartum fetal assessment. Cochrane Database Syst Rev. 2000; 2: CD001068.
Frusca, T, Todros, T, Lees, C, Bilardo, CM, TRUFFLE Investigators. Outcome in early-onset fetal growth restriction is best combining computerized fetal heart rate analysis with ductus venosus Doppler: insights from the Trial of Umbilical and Fetal Flow in Europe. Am J Obstet Gynecol. 2018; 218: S783–9.
Lalor, JG, Fawole, B, Alfirevic, Z, Devane, D. Biophysical profile for fetal assessment in high risk pregnancies. Cochrane Database Syst Rev. 2008; 1: CD000038.
Kaur, S, Picconi, JL, Chadha, R, Kruger, M, Mari, G. Biophysical profile in the treatment of intrauterine growth-restricted fetuses who weigh <1000 g. Am J Obstet Gynecol. 2008; 199: 264. e1–4.
Thornton, JG, Hornbuckle, J, Vail, A, Spiegelhalter, DJ, Levene, M, GRIT Study Group. Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial. Lancet. 2004; 364: 513–20.
Walker, DM, Marlow, N, Upstone, L, Gross, H, Hornbuckle, J, Vail, A, et al. The Growth Restriction Intervention Trial: long-term outcomes in a randomized trial of timing of delivery in fetal growth restriction. Am J Obstet Gynecol. 2011; 204: 34. e1–9.
Lees, CC, Marlow, N, van Wassenaer-Leemhuis, A, Arabin, B, Bilardo, CM, Brezinka, C, et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet. 2015; 385: 2162–72.
Ting, JY, Kingdom, JC, Shah, PS. Antenatal glucocorticoids, magnesium sulfate, and mode of birth in preterm fetal small for gestational age. Am J Obstet Gynecol. 2018; 218: S818–28.
Lee, HC, Gould, JB. Survival rates and mode of delivery for vertex preterm neonates according to small- or appropriate-for-gestational-age status. Pediatrics. 2006; 118: e1836–44.
Boers, KE, Vijgen, SM, Bijlenga, D, van der Post, JA, Bekedam, DJ, Kwee, A, et al. Induction versus expectant monitoring for intrauterine growth restriction at term: randomised equivalence trial (DIGITAT). BMJ. 2010; 341: c7087.
van Wyk, L, Boers, KE, van der Post, JA, van Pampus, MG, van Wassenaer, AG, van Baar, AL, et al. Effects on (neuro)developmental and behavioral outcome at 2 years of age of induced labor compared with expectant management in intrauterine growth-restricted infants: long-term outcomes of the DIGITAT trial. Am J Obstet Gynecol. 2012; 206: 406. e1–7.
Meher, S, Duley, L, Hunter, K, Askie, L. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2017; 216: 121–8. e2.
Groom, KM, David, AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol. 2018; 218: S829–40.
Rolnik, DL, Wright, D, Poon, LC, O’Gorman, N, Syngelaki, A, de Paco Matallana, C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New Engl J Med. 2017; 377: 613–22.
Wat, JM, Audette, MC, Kingdom, JC. Molecular actions of heparin and their implications in preventing pre-eclampsia. J Thromb Haemost. 2018 [ePub ahead of print].
Stockley, EL, Ting, JY, Kingdom, JC, McDonald, SD, Barrett, JF, Synnes, AR, et al. Intrapartum magnesium sulfate is associated with neuroprotection in growth-restricted fetuses. Am J Obstet Gynecol. 2018; 219: 606. e1–e8.
Nawathe, A, David, AL. Prophylaxis and treatment of foetal growth restriction. Best Pract Res Clin Obstet Gynaecol. 2018; 49: 66–78.
Wright, E, Audette, MC, Ye, XY, Keating, S, Hoffman, B, Lye, SJ, et al. Maternal vascular malperfusion and adverse perinatal outcomes in low-risk nulliparous women. Obstet Gynecol. 2017; 130: 1112–20.